Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine

Simple item page
dc.contributor.authorHaas, David
dc.contributor.authorArathoon, Eduardo
dc.contributor.authorThompson, Melanie
dc.contributor.authorde Jesus Pedro, Rogiero
dc.contributor.authorGallant, Joel E
dc.contributor.authorUip, David E
dc.contributor.authorCurrier, Judith
dc.contributor.authorNoriega, Miguel
dc.contributor.authorLewi, David
dc.contributor.authorUribe, Patricia
dc.contributor.authorBenetucci, Jorge
dc.contributor.authorCahn, Pedro
dc.contributor.authorPaar, David
dc.contributor.authorWhite, Clinton Jr
dc.contributor.authorCollier, Ann
dc.contributor.authorRamirez-Ronda, Carlos
dc.contributor.authorHarvey, Charlotte
dc.contributor.authorChung, Mi-ok
dc.contributor.authorMehrotra, Devan
dc.contributor.authorChodakewitz, Jeffrey
dc.contributor.authorNguyen, Bach-Yen
dc.date.accessioned2024-05-23T23:49:24Z
dc.date.available2024-05-23T23:49:24Z
dc.date.issued2000-09
dc.descriptionFil: Cahn, P. Fundación Huésped. Ciudad Autónoma de Buenos Aires; Argentina.es_ES
dc.description.abstractObjectives: To compare the efficacy and safety of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Design: Two multicenter, open-label, randomized 24-week studies. Methods: Adults HIV-1 infection, HIV-1 RNA greater than 10000 copies/ml, and no prior lamivudine or protease inhibitor therapy were eligible. In a pilot study (Study A), patients received indinavir at 800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h. In a subsequent study (Study B), patients received indinavir at 800 mg every 8 h or 1200 mg every 12 h. All subjects received zidovudine (300 mg) and lamivudine (150 mg) every 12 h. An intent-to-treat analysis was used. Results: In Study A, which enrolled 88 patients, neither HIV-1 RNA nor CD4 cell responses differed significantly between treatment groups at 24 weeks when corrected for multiple comparisons. Study B enrolled 433 patients, but was prematurely discontinued when interim analysis suggested greater efficacy of three-times-daily indinavir. Of the first 87 patients reaching week 24, HIV-1 RNA was less than 400 copies/ml in 91% receiving three-times-daily versus 64% receiving two-times-daily indinavir (P < 0.01). Conclusion: Three-times-daily indinavir appears more efficacious than two-times-daily dosing when administered with zidovudine and lamivudine. Two-times-daily indinavir dosing should only be considered in situations characterized by favorable pharmacokinetic drug-drug interactions.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1097/00002030-200009080-00013
dc.identifier.urihttps://journals.lww.com/aidsonline/Fulltext/2000/09080/Comparative_studies_of_two_times_daily_versus.13.aspx
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1351
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesAIDS;2000 Sep 8;14(13):1973-8. doi: 10.1097/00002030-200009080-00013.
dc.rightsopenAccesses_ES
dc.subjectResultado del Tratamientoes_ES
dc.subjectIndinavires_ES
dc.subjectZidovudinaes_ES
dc.subjectLamivudinees_ES
dc.titleComparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudinees_ES
dc.typeArticuloes_ES

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos